Hims & Hers Health, Inc. (HIMS) Stock Drops Despite Market Gains: Important Facts to Note

Hims & Hers Health (HIMS) closed down 3.73% at $47.79, underperforming the broader market and its sector, and has lagged over the past month. While analysts project robust year-over-year growth for upcoming earnings (50% EPS, 44.84% revenue) and full-year results (122.22% EPS, 58.91% revenue), the Zacks Consensus EPS estimate has seen a 6.27% downward revision in the last month, resulting in a Zacks Rank of #4 (Sell). The stock also trades at a significant premium with a Forward P/E of 82.99, well above its industry average of 31.96, though its PEG ratio of 3.35 aligns with the industry.

Analysis

Hims & Hers Health, Inc. (HIMS) presents a conflicting profile, characterized by strong long-term growth forecasts set against weak recent stock performance and deteriorating near-term analyst sentiment. The stock's 3.73% decline in the last session and 0.68% loss over the past month sharply contrast with gains in the broader market and the Medical sector. While consensus estimates point to exceptional future growth—projecting 44.84% YoY revenue growth for the upcoming quarter and 122.22% EPS growth for the full year—these bullish fundamentals are undermined by several cautionary signals. Notably, the Zacks Consensus EPS estimate has been revised downward by 6.27% within the past month, contributing to a bearish Zacks Rank of #4 (Sell). Furthermore, the stock's valuation is steep, with a Forward P/E ratio of 82.99, significantly above the industry average of 31.96. Although its PEG ratio of 3.35 aligns with the industry, suggesting the valuation is tied to its high growth expectations, the combination of negative estimate revisions and recent market underperformance indicates that investors are becoming skeptical of the premium.

Key Decisions for Investors

• Investors should exercise caution due to the stock's high valuation; the Forward P/E of 82.99 suggests that aggressive growth is already priced in, making the stock vulnerable to a significant correction if earnings fail to meet lofty expectations.
• The recent 6.27% downward revision in consensus EPS estimates and the resulting Zacks Rank of #4 (Sell) are significant negative indicators that warrant close attention, as they signal potential near-term headwinds and weakening analyst confidence.
• It may be prudent to await the upcoming earnings report as a key catalyst, which will either validate the company's aggressive growth narrative or confirm the bearish sentiment reflected in the stock's recent underperformance and negative analyst revisions.